

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



DOCMODE HEALTH TECHNOLOGIES LIMITED

CIN: U74999MH2017PLC297413

Our Company was incorporated in Mumbai, Maharashtra, as a "Docmode Health Technologies Private Limited", a private limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated July 17, 2017 issued by the Deputy Registrar of Companies, Central Registration Centre. Thereafter, our Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by our Shareholders at the Extraordinary General Meeting held on December 15, 2022, and consequent upon conversion, the name of our Company was changed to "Docmode Health Technologies Limited" and a fresh certificate of incorporation dated January 2, 2023 bearing Corporate Identity Number U74999MH2017PLC297413 issued by Registrar of Companies, Maharashtra, Mumbai. For further details, please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 143 of the Prospectus.

Registered Office: 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad Mumbai, -400064, Maharashtra, India | **Tel No:** +91 9920923338 | **Contact Person:** Reshma Susan, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY: PAULSON PAUL THAZHATHEDATH AND HANS ALBERT LEWIS

THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE LIMITED ("NSE EMERGE")

Our Company has filed the Prospectus dated January 18, 2024 with the RoC and trading of the Equity Shares Allotted pursuant to the Issue is expected to commence on February 02, 2024.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 8,49,600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF DOCMODE HEALTH TECHNOLOGIES LIMITED ("THE COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹79/- PER EQUITY SHARE (THE "ISSUE PRICE"), (INCLUDING A PREMIUM OF ₹ 69/- PER EQUITY SHARE), AGGREGATING ₹ 671.184 LAKHS ("THE ISSUE"), OF WHICH 43,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- FOR CASH AT A PRICE OF ₹79/- EACH AGGREGATING ₹34.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 8,06,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹79/- PER EQUITY SHARE, AGGREGATING TO ₹ 637.05 LAKHS IS HERE IN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.03 % AND 25.66% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF THE COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO CHAPTER TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE NO 239 OF THE PROSPECTUS.

RISKS TO INVESTORS																				
<div><div><div>1. We are dependent on our relationships with healthcare professionals, and our business and financial results could be to an extent impacted if we are not able to engage such healthcare professionals on a regular basis.</div><div>2. Our ability to retain the present number of learners and professionals serviced by us and attract new learners and professionals is dependent upon various factors including our reputation and our ability to maintain a high level of service quality. Any failure by us to retain or attract learners and professionals may impact our business and its revenues.</div><div>3. Our Company is yet to place orders for the purchase of IT infrastructure and operating system. Any delay in placing orders or procurement of such machinery may delay the schedule of implementation</div><div>4. The business in which we operate is specifically regulated. The central and state governments may change the existing regulations or introduce a new regulatory framework in the future. The impact of such changes or new regulations on the business cannot be ascertained presently and may affect our business adversely in the future.</div><div>5. Our success depends significantly on our ability to continue to innovate and implement technological advances. If we are unable to keep pace with evolving technology and user preferences, our business, results of operations and prospects may be adversely affected.</div><div>6. There have been some instances of delay/default in payment of statutory dues by our Company in the past.</div><div>7. Strong competition in the business of providing professional medical learning could also decrease our market share and compel us to reduce course fees or provide higher discounts on our course fees. This may have a material adverse impact on the number of learners and health care professionals enrolled with us, revenues and profitability.</div><div>8. Any disruption in our information technology systems may adversely affect our business, results of operations and prospects.</div></div><div><div>9. WEIGHTED AVERAGE PRICE AT WHICH THE EQUITY SHARES WERE ACQUIRED BY OUR PROMOTERS IN THE ONE YEAR PRECEDING THE DATE OF THE PROSPECTUS</div><div>The weighted average price at which the equity shares were acquired by our Promoters in the one year preceding the date of the Prospectus.</div><table><tr><th>Name</th><th>Number of Shares</th><th>Weighted Average Cost of Acquisition per Equity Share (in Rs.)*</th></tr><tr><td>Paulson Paul Thazhathedath</td><td>335790</td><td>Nil</td></tr><tr><td>Hans Albert Lewis</td><td>335790</td><td>Nil</td></tr></table><div>*As certified by R Sundaresan Aiyar & Co, Chartered Accountants, pursuant to their certificate dated January 18, 2024</div><div>10. AVERAGE COST OF ACQUISITION</div><div>The average cost of acquisition per Equity Share to our Promoters as at the date of the Prospectus is:</div><table><tr><th>Name</th><th>Number of Shares</th><th>Average Cost of Acquisition per Equity Share (in Rs.)</th></tr><tr><td>Paulson Paul Thazhathedath</td><td>7,45,290</td><td>0.65</td></tr><tr><td>Hans Albert Lewis</td><td>7,45,290</td><td>0.65</td></tr></table><div>*As certified by R Sundaresan Aiyar & Co, Chartered Accountants, pursuant to their certificate dated January 18, 2024.</div></div></div>			Name	Number of Shares	Weighted Average Cost of Acquisition per Equity Share (in Rs.)*	Paulson Paul Thazhathedath	335790	Nil	Hans Albert Lewis	335790	Nil	Name	Number of Shares	Average Cost of Acquisition per Equity Share (in Rs.)	Paulson Paul Thazhathedath	7,45,290	0.65	Hans Albert Lewis	7,45,290	0.65
Name	Number of Shares	Weighted Average Cost of Acquisition per Equity Share (in Rs.)*																		
Paulson Paul Thazhathedath	335790	Nil																		
Hans Albert Lewis	335790	Nil																		
Name	Number of Shares	Average Cost of Acquisition per Equity Share (in Rs.)																		
Paulson Paul Thazhathedath	7,45,290	0.65																		
Hans Albert Lewis	7,45,290	0.65																		

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10.00/- EACH AND

THE ISSUE PRICE IS ₹79 PER EQUITY SHARE

THE ISSUE PRICE IS 7.9 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

ISSUE OPENED ON: January 25, 2024

ISSUE CLOSED ON: January 29, 2024

PROPOSED LISTING

The Equity Shares of the Company offered through the Prospectus dated January 18, 2024 are proposed to be listed on the NSE Emerge in terms of the Chapter IX of SEBI (ICDR) Regulations, 2018 as amended from time to time. Our Company has received In-Principle Approval Letter dated August 22, 2023 from NSE Limited for listing our shares and also for using its name in the Issue document for listing of our shares on NSE Emerge. It is to be distinctly understood that the permission given by NSE Limited should not in any way be deemed or construed that the Issue Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Issue Document. The investors are advised to refer to the Prospectus for the full text of the "Disclaimer Clause of the Emerge Platform of NSE Limited" on page 230 of the Prospectus. For the purpose of this issue the Designated Stock Exchange will be NSE Emerge. The trading is proposed to be commenced on February 02, 2024 (Subject to receipt of listing and trading approval from NSE Limited).

This issue is being made through Fixed Price Process in terms of Chapter IX of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI (ICDR) Regulations") as amended and Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR"). According to Regulation 25(2) of the SEBI (ICDR) Regulations, 2018 as amended from time to time, the allocation in the Net Issue to the Public category is made as follows: (a) minimum 50% of the net issue of shares shall be allocated to Retail Individual Investors and (b) remaining to: (i) Individual applicants other than retail individual investors; and (ii) other investors including corporate bodies or institutions, irrespective of number of specified securities applied for; provided that the unsubscribed portion in either of categories specified in clauses (a) or (b) may be allocated to applicants in the other category.

If the retail individual investor category is entitled to more than allocated portion on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage. For further details, please refer to chapter titled "Issue Structure" beginning on page no. 250 of the Prospectus.

All investors have participated in this issue through Application Supported by Blocked Amount ("ASBA") process including through Unified Payment Interface ("UPI") mode (as applicable) by providing the details of the respective bank accounts/ UPI ID as applicable in which the corresponding application amounts were blocked by Self Certified Syndicate Banks (the "SCSBs")/ Sponsor Bank as the case may be.

DETAILS OF THE APPLICATION:

The issue was subscribed to the extent of 243.62 times as per the bid books of NSE (the "Bid Files") after removing multiple and duplicate bids.

The details of the applications received in the Issue from Retail Individual Investors, Non-Institutional Investors and Market Maker (before and after technical rejections & withdrawal) are as follows:

DETAILS OF APPLICATIONS RECEIVED (before technical rejection)

Category	Number of applications	Number of equity shares Bid for	Number of equity shares reserved as per Prospectus	Number of times subscribed
Market Maker	1	43,200	43,200	1.00
Non - Retail Individual Investor's	7,707	7,85,85,600	4,03,200	194.90
Retail Individual Investor's	58,072	9,29,15,200	4,03,200	230.44
TOTAL	65,780	17,15,44,000	8,49,600	201.91

DETAILS OF VALID APPLICATIONS:

Sr. No.	Category	Gross		Less: Rejections*		Valid	
		Applications	Equity Shares	Applications	Equity Shares	Applications	Equity Shares
1	Market Maker	1	43,200	-	-	1	43,200
2	Non-Retail Investors	7,707	7,85,85,600	91	4,08,000	7,616	7,81,77,600
3	Retail Individual Investors	58,072	9,29,15,200	908	14,52,800	57,164	9,14,62,400
Total		65,780	17,15,44,000	999	18,60,800	64,781	16,96,83,200

*This includes 17 applications for 27,200 equity shares from Retail investors which were not in book but excludes bids (UPI mandates) not accepted by investors.

A. ALLOCATION: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange i.e NSE Limited on January 31, 2024.

B. Allocation to Market Maker (After Technical Rejections): The Basis of Allotment to the Market Maker, at the issue price of ₹79/- per Equity Share, was finalised in consultation with NSE Emerge. The category was subscribed by 1 time. The total number of shares allotted in this category is 43,200 Equity shares in full out of reserved portion of 43,200 Equity Shares.

C. Allocation to Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Retail Individual Investors, at the issue price of ₹79/- per Equity Share, was finalised in consultation with NSE Emerge. The category was subscribed by 226.84 times. The total number of shares allotted in this category is 4,35,200 Equity shares out of reserved portion of 4,03,200 Equity Shares.

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Allocation per Applicant	Ration of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/allotted	% to total
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(14)
1	1,600	57,164	100.00	9,14,62,400	100.00	4,35,200	7.61	1,600	1	210	272	100.00
GRAND TOTAL	57,164	100.00	9,14,62,400	100.00	4,35,200				272	100.00	4,35,200	100.00

D. Allocation to Non- Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Non-Retail Individual Investors, at the issue price of ₹79/- per Equity Share, was finalised in consultation with NSE Limited. The category was subscribed by 193.89 times. The total number of shares allotted in this category is 3,71,200 Equity shares out of reserved portion of 4,03,200 Equity Shares.

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Allocation per Applicant	Ration of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/allotted	% to total
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(14)
1	3200	5133	67.40	16425600	21.01	77991	15.19	1600	4	419	49	23.56
2	4800	602	7.91	2889600	3.70	13720	22.79	1600	9	602	9	4.33
3	6400	253	3.32	1619200	2.07	7688	30.39	1600	5	253	5	2.40
4	8000	179	2.35	1432000	1.83	6799	37.98	1600	4	179	4	1.92
5	9600	97	1.27	931200	1.19	4422	45.58	1600	3	97	3	1.44
6	11200	155	2.04	1736000	2.22	8243	53.18	1600	1	31	5	2.40
7	12800	497	6.53	6361600	8.14	30206	60.78	1600	19	497	19	9.14
8	14400	124	1.63	1785600	2.28	8478	68.37	1600	5	124	5	2.40
9	16000	153	2.01	2448000	3.13	11624	75.97	1600	7	153	7	3.37
10	17600	24	0.32	422400	0.54	2006	83.58	1600	1	24	1	0.48
11	19200	38	0.50	729600	0.93	3464	91.16	1600	1	19	2	0.96
12	20800	10	0.13	208000	0.27	988	98.8	1600	1	10	1	0.48
13	22400	15	0.20	336000	0.43	1595	106.33	1600	1	15	1	0.48
14	24000	32	0.42	768000	0.98	3647	113.97	1600	1	16	2	0.96
15	25600	20	0.26	512000	0.65	2431	121.55	1600	1	20	1	0.96
16	27200	5	0.07	136000	0.17	646	129.2	1600	0	0	0	0.00
17	28800	25	0.33	720000	0.92	3419	136.76	1600	2	25	2	0.96
18	30400	3	0.04	91200	0.12	433	144.33	1600	0	0	0	0.00
19	32000	35	0.46	1120000	1.43	5318	151.94	1600	3	35	3	1.44
20	33600	7	0.09	235200	0.30	1117	159.57	1600	1	7	1	0.48
21	35200	5	0.07	176000	0.23	836	167.2	1600	0	0	0	0.48
22	36800	4	0.05	147200	0.19	699	174.75	1600	0	0	0	0.00
23	38400	7	0.09	268800	0.34	1276	182.29	1600	1	7	1	0.48
24	40000	7	0.09	280000	0.36	1330	189.86	1600	1	7	1	0.48
25	43200	4	0.05	172800	0.22	820	205	1600	0	0	0	0.48
26	44800	2	0.03	89600	0.11	425	212.5	1600	0	0	0	0.00
27	46400	2	0.03	92800	0.12	441	220.5	1600	0	0	0	0.00
28	48000	11	0.14	528000	0.68	2507	227.91	1600	2	11	2	0.96
29	49600	1	0.01	49600	0.06	236	236	1600	0	0	0	0.00
30	51200	2	0.03	102400	0.13	486	243	1600	0	0	0	0.00
31	52800	1	0.01	52800	0.07	251	251	1600	0	0	0	0.00
32	54400	5	0.07	272000	0.35	1292	258.4	1600	1	5	1	0.48
33	56000	4	0.05	224000	0.29	1064	266	1600	1	4	1	0.48
34	57600	1	0.01	57600	0.07	274	273	1600	0	0	0	0.00
35	59200	2	0.03	118400	0.15	562	281	1600	0	0	0	0.00
36	62400	4	0.05	249600	0.32	1185	296.25	1600	1	4	1	0.48
37	64000	9	0.12	576000	0.74	2735	303.89	1600	2	9	2	0.96
38	65600	3	0.04	196800	0.25	934	311.33	1600	1	3	1	0.48
39	70400	2	0.03	140800	0.18	669	334.5	1600	0	0	0	0.00
40	72000	5	0.07	360000	0.46	1709	341.8	1600	1	5	1	0.48
GRAND TOTAL	7,616	100.00	7,81,77,600	100.00	3,71,201							

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Allocation per Applicant	Ration of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/allotted	% to total
41	73600	1	0.01	73600	0.09	349	349	1600	0	0	0	0.00
42	75200	2	0.03	150400	0.19	714	357	1600	0	0	0	0.00
43	78400	3	0.04	235200	0.30	1117	372.33	1600	1	3	1	0.48
44	80000	5	0.07	400000	0.51	1899	379.8	1600	1	5	1	0.48
45	81600	3	0.04	244800	0.31	1162	387.33	1600	1	3	1	0.48
46	83200	2	0.03	166400	0.21	790	395	1600	0	0	0	0.00
47	84800	3	0.04	254400	0.33	1208	402.67	1600	1	3	1	0.48
48	88000	3	0.04	264000	0.34	1255	418	1600	1	3	1	0.48
49	94400	3	0.04	283200	0.36	1345	448.33	1600	1	3	1	0.48
50	96000	2	0.03	192000	0.25	912	456	1600	1	2	1	0.48
51	100800	8	0.11	806400	1.03	3829	478.63	1600	1	4	2	0.96
52	104000	3	0.04	312000	0.40	1481	493.67	1600	1	3	1	0.48
53	110400	2	0.03	220800	0.28	1048	524	1600	1	2	1	0.48
54	115200	1	0.01	115200	0.15	547	547	1600	0	0	0	0.00
55	116800	2	0.03	233600	0.30	1109	554.5	1600	1	2	1	0.48
56	120000	1	0.01	120000	0.15	570	570	1600	0	0	0	0.00
57	121600	1	0.01	121600	0.16	577	577	1600	0	0	0	0.00
58	124800	1	0.01	124800	0.16	593	593	1600	0	0	0	0.00
59	126400	6	0.08	758400	0.97	3601	600.17	1600	1	3	2	0.96
60	128000	3	0.04	384000	0.49	1823	607.67	1600	1	3	1	0.48
61	131200	1	0.01	131200	0.17	623	623	1600	0	0	0	0.00
62	132800	2	0.03	265600	0.34	1261	630.5	1600	1	2	1	0.48
63	137600	1	0.01	137600	0.18	653	653	1600	0	0	0	0.00
64	139200	2	0.03	278400	0.36	1322	661	1600	1	2	1	0.48
65	142400	3	0.04	427200	0.55	2028	676	1600	1	3	1	0.48
66	145600	1	0.01	145600	0.19	691	691	1600	0	0	0	0.00
67	153600	1	0.01	153600	0.20	729	729	1600	0	0	0	0.00
68	155200	2	0.03	310400	0.40	1474	737	1600	1	2	1	0.48
69	160000	2	0.03	320000	0.41	1519	759.5	1600	1	2	1	0.48
70	161600	1	0.01	161600	0.21	767	767	1600	0	0	0	0.00
71	163200	2	0.03	326400	0.42	1550	775	1600	1	2	1	0.48
72	164800	1	0.01	164800	0.21	783	782	1600	0	0	0	0.00
73	169600	1	0.01	169600	0.22	805	805	1600	0	0	0	0.48
74	180800	1	0.01	180800	0.23	858	858	1600	0	0	0	0.48
75	184000	1	0.01	184000	0.24	874	874	1600	1	1	1	0.48
76	187200	1	0.01	187200	0.24	889	889	1600	1	1	1	0.48
77	188800	1	0.01	188800	0.24	896	896	1600	1	1	1	0.48
78	196800	1	0.01	196800	0.25	934	934	1600	1	1	1	0.48
79	198400	1	0.01	198400	0.25	942	942	1600	1	1	1	0.48
80	203200	2	0.03	406400	0.52	1930	965	1600	1	2	1	0.48
81	206400	1	0.01	206400	0.26	980	980	1600	1	1	1	0.48
82	208000	1	0.01	208000	0.27	988	988	1600	1	1	1	0.48
83	211200	1	0.01	211200	0.27	1003	1003	1600	1	1	1	0.48
84	217600	1	0.01	217600	0.28	1033	1033	1600	1	1	1	0.48
85	220800	1	0.01	220800	0.28	1048	1048	1600	1	1	1	0.48
86	222400	1	0.01	222400	0.28	1056	1056	1600	1	1	1	0.48
87	225600	1	0.01	225600	0.29	1071	1071	1600	1	1	1	0.48
88	232000	1	0.01	232000	0.30	1102	1102	1600	1	1	1	0.48
89	240000	1	0.01	240000	0.31	1140	1140	1600	1	1	1	0.48
90	252800	1	0.01	252800	0.32	1200	1200	1600	1	1	1	0.48
91	260800	1	0.01	260800	0.33	1238	1238	1600	1	1	1	0.48
92	265600	1	0.01	265600	0.34	1261	1261	1600	1	1	1	0.48

Continued from previous page

The Board of Directors of the Company at its meeting held on January 31, 2024 has taken on record the Basis of Allotment of Equity Shares, as approved by the Designated Stock Exchange viz. NSE Emerge and has authorized the online corporate action for the allotment of the Equity Shares in dematerialised form to various successful applicants. The CAN-cum-Refund Orders and Allotment Advice and/or Notices are being dispatched to the address of the applicants as registered with the depositories / as filled in the application form on February 01, 2024. Further, the instructions to Self-Certified Syndicate Banks being processed on January 31, 2024 for unblocking fund. In case the same is not received in compliance with the applicable timeline, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The company shall file the listing application with NSE Limited on or before February 01, 2024. The Company is in process of obtaining the listing & the trading approval from NSE Limited and the trading is expected to commence on February 02, 2024.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as Ascribed to them in the Prospectus dated January 18, 2024.

DISCLOSURES PERTAINING TO THE LM'S TRACK RECORD ON PAST ISSUES WITH A BREAKUP OF HANDLING OF SME IPOs FOR THE LAST 3 YEARS: FEDEX SECURITIES PRIVATE LIMITED

TYPE	FY 2020-21	FY 2021-22	FY 2022-23
SME IPO	2	5	7
MAIN BOARD	0	0	0

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, **Bigshare Services Private Limited** at ipo@bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the first/ sole applicants, serial number of the application form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:



BIGSHARE SERVICES PRIVATE LIMITED
Office No. S6 - 2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Cave Road, Andheri - [East], Mumbai - 400093, Maharashtra, India.
Tel No: +91 22 6263 8200
Fax No: +91 22 6263 8299
E-mail Id: ipo@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Mr. Aniket Chindarkar
SEBI Registration No: INR000001385



LEAD MANAGER TO THE ISSUE
FEDEX SECURITIES PRIVATE LIMITED
B 7, 3rd Floor, Jay Chambers, Dayaldas Road, Vile Parle (East), Mumbai - 400 057, Maharashtra, India
Telephone +91 81049 85249
E-mail: mb@fedsec.in
Investor Grievance E-Mail: mb@fedsec.in
Website: www.fedsec.in
Contact Person: Mr. Saipan Sanghvi
SEBI Registration Number: INM000010163

Date: January 31, 2024
Place: Mumbai, Maharashtra

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF DOCMODE HEALTH TECHNOLOGIES LIMITED.

The Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of the Lead Manager at www.fedsec.in, website of the National Stock Exchange of India Limited at www.nseindia.com and website of Issuer Company at www.docmode.org For details, investors should refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page 27 of the Prospectus.

The Equity Shares offered in this Issue have not been and will not be registered under the US Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

FOR DOCMODE HEALTH TECHNOLOGIES LIMITED
On behalf of the Board of Directors
Sd/-
Paulson Paul Thazhathadath
Designation: Managing Director
DIN: 02301881

NOTICE



Investor Awareness Program (IAP)

Investor awareness programs are scheduled to be held virtually on the below mentioned dates at 3.00 p.m. For any queries/clarifications contact +91-7900005528.

Dates of the Investor awareness programs and the links for joining the online webinar are given below:

Dates of the event	Links for joining online webinar
February 03, 2024	https://us06web.zoom.us/join/register/WN_rqhz2qfhQL2LjCxy5dzMlw
February 10, 2024	https://us06web.zoom.us/join/register/WN_cs02ZglsRoGjSdX6oHKKcw
February 17, 2024	https://us06web.zoom.us/join/register/WN_k8QgABQCR1OR8jir3P0cNA
February 24, 2024	https://us06web.zoom.us/join/register/WN_Ry8U_oaRTaKG56StJw-hw

For Kotak Mahindra Asset Management Company Limited
Investment Manager – Kotak Mahindra Mutual Fund

Mumbai
January 31, 2024

Sd/-
Authorised signatory

Any queries / clarifications in this regard may be addressed to:
Kotak Mahindra Asset Management Company Limited
CIN: U65991MH1994PLC080009 (Investment Manager for Kotak Mahindra Mutual Fund)
6th Floor, Kotak Towers, Building No. 21, Infinity Park, Off: Western Express Highway,
Goregaon - Mulund Link Road, Malad (East), Mumbai 400097.
Phone Number: 18003091490 / 044-40229101 • Email: readall@kotak.com • Website: kotakmf.com

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

CJ DARCL LOGISTICS LIMITED

Regd. Office: DARCL House,
Plot No. 55P, Institutional Area,
Sector-44, Gurugram - 122003
Ph. No.: +91-9015202121
Fax: +91-124 4034162
Email: compliance@cjdarcl.com
CIN: U60222HR1986PLC068818
Website: www.cjdarcl.com

NOTICE FOR VENDORS OF CJ DARCL LOGISTICS LIMITED

Notice is hereby given that as per notification dated 02/11/2018 and order that 22/01/2019 issued by Ministry of Corporate Affairs, Company is in process of identifying suppliers / traders / Service providers who falls in the category of Micro, Small and Medium Enterprises under Micro, Small and Medium Enterprises Development (MSMED) Act, 2006.

Suppliers / traders / Service providers who are associated with the Company are hereby requested to confirm whether their enterprise is a Micro / Small / Medium enterprise. The copy of registration certificate along with confirmation be sent at e-mail id compliance@cjdarcl.com or be posted at kind attention : Company Secretary, CJ Darcl Logistics Limited, Darcl House, Plot No. 55 P Sector-44, Institutional Area, Gurugram, Haryana, 122003. The purpose of seeking this information from our vendors is to ascertain their status under (MSMED) Act, 2006 for reporting purpose and finalization of our balance sheet accordingly as per the Companies Act 2013. Please note if we do not receive the above confirmation with copy of certificate within 10 days of publication of this notice, we will presume that vendors do not qualify as a micro, small or medium enterprise under MSMED Act, 2006.

For CJ Darcl Logistics Limited
Sd/-
Company Secretary

SHREE DIGVIJAY CEMENT COMPANY LIMITED (CIN: L26940GJ1944PLC000749)

Registered Office: DIGVIJAYGRAM 361 140 Via: Jamnagar, Gujarat, India
Tel: +91 288 2344 272 -2344 275
Website: www.digvijaycement.com Email: investors.sdcl@digvijaycement.com

NOTICE OF POSTAL BALLOT

Members are hereby informed that pursuant to Section 108 and Section 110 of the Companies Act, 2013 (the Act) read with the Companies (Management and Administration) Rules, 2014 (Rules), read with the General Circular Nos. 14/2020 dated 8th April, 2020, 17/2020 dated 13th April, 2020 and the latest one being General Circular No. 9/2023 dated 25th September, 2023 issued by the Ministry of Corporate Affairs (MCA Circulars) read with SEBI Circular dated 12th May, 2020, Circular dated 15th January, 2021, Circular dated 13th May, 2022, Circular dated 5th January, 2023 and Circular dated 7th October, 2023 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and any other applicable provisions of the Acts, Rules, Regulations, Circulars and Notifications issued thereunder (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time), the Company has on Wednesday, 31st January, 2024, sent Notice of Postal Ballot dated 19th January, 2024, together with an Explanatory Statement pursuant to Section 102 of the Act to the members of the Company, whose E-mail address is registered with the Company/ RTA.

The Board of Directors of the Company has appointed Mr. Manoj R Hurkat (FCS No.: 4287 / COP.No.: 2574), Practising Company Secretary as Scrutinizer for conducting the Postal Ballot process, in a fair and transparent manner

Members are requested to provide their consent or dissent through e-voting only. The Company has availed the services of National Securities Depository Limited ("NSDL") for facilitating e-voting to enable the Shareholders to cast their votes electronically. The detailed procedure for e-voting is enumerated in the Notes to the Postal Ballot Notice.

The details of e-voting period are as under:

Cut-off Date	29 th January ,2024
Commencement of e-voting	5 th February, 2024
Conclusion of e-voting	5 th March, 2024

A person who is not a Member as on the 'Cut-off date' should treat the Notice of Postal Ballot for information purpose only. The copy of the Postal Ballot Notice is available on the Company's website at www.digvijaycement.com, websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively, and on the website of National Securities Depository Limited at evoting.nsdl.com. Members who do not receive the Postal Ballot Notice may download it from the above mentioned websites.

Members holding shares in physical mode and who have not updated their email addresses with the Company are requested to update their email addresses by writing to the Company at investors.sdcl@digvijaycement.com along with the copy of the signed request letter in Form [SR-1 mentioning the name and address of the Member, self-attested copy of the PAN card, and self-attested copy of any document (eg.: Driving License, Election Identity Card, Passport) in support of the address of the Member. Members holding shares in dematerialised mode are requested to register / update their email addresses with the relevant Depository Participants. In case of any queries / difficulties in registering the email address, Members may write to investors.sdcl@digvijaycement.com

In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on: 022 - 4886 7000 and 022 - 2499 7000. For any grievances regarding e-voting or any queries related thereto, you may contact Ms. Pallavi Mhatre, NSDL, 4th Floor, 'A' Wing, Trade World, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai 400 013, e-mail: evoting@nsdl.co.in or call on: 022 - 4886 7000 and 022 - 2499 7000

The result of the e-voting by Postal Ballot will be announced on Wednesday, 6th March, 2024 at the Registered Office of the Company and shall be available on the Company's website at www.digvijaycement.com and on NSDL's website: www.evoting.nsdl.com.

For Shree Digvijay Cement Company Limited

Sd/-

Suresh Meher

Date : 31st January, 2024

Place: Ahmedabad

VP (Legal) & Company Secretary

ACS No.: 16938

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



(Please scan this QR Code to view the Notice)



JNK INDIA LIMITED

Our Company was incorporated as "JNK India Private Limited", a private limited company under the Companies Act, 1956 in Thane, Maharashtra, pursuant to a certificate of incorporation dated June 14, 2010, granted by the Registrar of Companies, Maharashtra at Mumbai ("RoC"). Pursuant to the conversion of our Company from a private limited company into a public limited company and as approved by our Board on April 12, 2023, and a special resolution passed by our Shareholders at the EGM on April 14, 2023, the name of our Company was changed to "JNK India Limited", and the RoC issued a fresh certificate of incorporation on May 26, 2023. For details of change in the Registered Office, see "History and Certain Corporate Matters - Changes in the Registered Office" on page 180 of the DRHP.

Registered and Corporate Office: Unit No. 203, 204, 205 & 206, Opposite TMC Office Centrum IT Park, Near Satkar Hotel, Thane - West, Thane 400 604, Maharashtra, India
Tel: +91 22 6885 8000; Contact Person: Ashish Soni, Company Secretary and Compliance Officer; Tel: +91 22 6885 8000; E-mail: compliance@jnkindia.com;
Website: www.jnkindia.com; Corporate Identity Number: U29268MH2010PLC204223

NOTICE TO INVESTORS ("NOTICE")

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF JNK INDIA LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹ [•] MILLION (THE "OFFER"), COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES AGGREGATING UP TO ₹ 3,000.00 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 8,421,052 EQUITY SHARES (THE "OFFERED SHARES") AGGREGATING UP TO ₹ [•] MILLION (THE "OFFER FOR SALE"). THE OFFER WILL CONSTITUTE [•]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

Potential Bidders may note the following:

a) On November 30, 2023, one of our Promoters, Dipak Kacharalul Bharuka transferred 4,960,000 Equity Shares to Bharuka Family Private Trust ("Trust"), a family private trust managed by Amicorp Trustees India Private Limited as its trustee ("Trustee") established vide a trust deed executed on February 22, 2023 ("Trust Deed"), wherein Dipak Kacharalul Bharuka and his wife Priya Bharuka are the primary beneficiaries, by way of a gift, for no consideration ("Transfer"). Except for Dipak Kacharalul Bharuka, one of our Promoters, Directors and Key Managerial Personnel and Priya Bharuka, one of the members of the Promoter Group of Dipak Kacharalul Bharuka, the Trust is not connected with our Company, our Promoters, our Promoter Group, our Directors, our Key Managerial Personnel, our Subsidiaries, our Group Companies and their respective directors and key managerial personnel.

b) Further, on January 30, 2024, the Trust transferred 4,960,000 Equity Shares to one of our Promoters, Dipak Kacharalul Bharuka, by way of a gift, for no consideration ("Reverse Transfer").

The details of Transfer and Reverse Transfer are provided below:

Date of Transaction/Transfer	Name of Transferor	Name of Transferee/ Acquirer/Allottee	Nature of Transfer	Number of Equity Shares Transferred	Transfer Price per Equity Shares (in ₹)
November 30, 2023	Dipak Kacharalul Bharuka	Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	Gift	4,960,000	Nil
January 30, 2024	Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	Dipak Kacharalul Bharuka	Gift	4,960,000	Nil

Details of the shareholding of the Trust and Dipak Kacharalul Bharuka set forth below:

a) Shareholding of Dipak Kacharalul Bharuka and the Trust in the Company, prior to and subsequent to the Transfer-

S. No.	Date of Transaction /Transfer	Name	Pre-Transfer Shareholding		Post-Transfer Shareholding	
			No. of Equity Shares	Percentage of pre-Offer share capital of the Company (%)	No. of Equity Shares	Percentage of pre-Offer share capital of the Company (%)
I.	November 30, 2023	Dipak Kacharulal Bharuka	4,960,000	10.25	-	-
		Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	-	-	4,960,000	10.25

b) Shareholding of the Trust and Dipak Kacharalul Bharuka in the Company, prior to and subsequent to the Reverse Transfer-

S. No.		Date of Transaction /Transfer	Name	Pre-Transfer Shareholding		Post-Transfer Shareholding	
				No. of Equity Shares	Percentage of pre-Off share capital of the Company (%)	No. of Equity Shares	Percentage of pre-Off share capital of the Company (%)
1.		January 30, 2024	Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	4,960,000	10.25	-	-
			Dipak Kacharalul Bharuka	-	-	4,960,000	10.25

BOOK RUNNING LEAD MANAGERS	REGISTRAR TO THE OFFER
IIFL SECURITIES IIFL Securities Limited 24 th Floor, One Lodha Place Senapati Bapat Marg, Lower Parel (West), Mumbai 400 013 Maharashtra, India Tel: +91 22 4646 4728 E-mail: jnk.ipo@iiflcap.com Investor grievance e-mail: ig_ib@iiflcap.com Website: www.iiflcap.com Contact person: Mukesh Garg/ Pawan Jain SEBI registration no.: INM000010940	ICICI Securities ICICI Securities Limited ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025 Maharashtra, India Tel: +91 810 811 4949 E-mail: jnk.ipo@icicisecurities.com Investor grievance e-mail: customeercare@icicisecurities.com Website: www.icicisecurities.com Contact person: Namrata Ravasia/ Harsh Thakkar SEBI registration no.: INM000011779



Link Intime India Private Limited
C-101, 1st Floor, 247 Park, L.B.S. Marg,
Vikhroli West, Mumbai 400 083 Maharashtra, India
Tel: +91 810 811 4949
E-mail: jnkindia.ipo@linkintime.co.in
Website: www.linkintime.co.in
Investor grievance e-mail: jnkindia.ipo@linkintime.co.in
Contact person: Shanti Gopalakrishnan
SEBI Registration No.: INR000004058

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For JNK INDIA LIMITED

Sd/-

Ashish Soni

Company Secretary and Compliance Officer

JNK India Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed the DRHP with the Securities and Exchange Board of India ("SEBI") and the Stock Exchanges. The DRHP is available on the websites of the Company at www.jnkindia.com, SEBI at www.sebi.gov.in, the book running lead managers, IIFL Securities Limited and ICICI Securities Limited at www.iiflcap.com and www.icicisecurities.com, respectively, and National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the DRHP on page 28, when available. Potential investors should not rely on the DRHP filed with SEBI for any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in reliance on the exemption from registration under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made.

CONCEPT



POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110020
CIN: L40300DL1995PLC066923, Phone: 011-26321889, Fax: 011-26321894
Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED DECEMBER 31, 2023

Particulars	Standalone			Consolidated		
	Quarter Ended	Nine Month Ended	Quarter Ended	Quarter Ended	Nine Month Ended	Quarter Ended
	31.12.2023 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)
1 Total Income from operations	33,742.84	98,883.83	28,608.70	35,616.58	104,149.72	29,925.99
2 Net Profit/(Loss) for the period (before tax, Exceptional and/or Extraordinary items)	8,208.97	24,092.16	6,432.19	8,782.46	25,181.23	6,679.25
3 Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	8,208.97	24,092.16	6,432.19	8,782.46	25,181.23	6,679.25
4 Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	6,146.08	18,119.09	4,753.96	6,501.59	18,990.18	5,001.02
5 Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,151.04	18,034.69	4,746.47	6,526.24	18,910.23	5,106.71
6 Equity paid up share capital	4,797.23	4,797.23	4,795.91	4,797.23	4,797.23	4,795.91
7 Earnings per share (Face value of ₹ 5 Each) (Quarterly not annualised):						
Basic (₹)	6.41	18.89	4.95	6.78	19.79	5.21
Diluted (₹)	6.40	18.87	4.95	6.77	19.77	5.20

Notes:

- The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 31st January, 2024 and have also been limited reviewed by Statutory auditors of the Company.
- The above is an extract of the detailed format of unaudited Standalone and Consolidated Financial Results for the quarter and Nine Months ended December 31, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com.

By order of the Board

Sd/-

Rishi Bald

Joint Managing Director

Place: New Delhi

Date : 31st January 2024